GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (LTS:0J2O) » Definitions » 5-Year Yield-on-Cost %

Halozyme Therapeutics (LTS:0J2O) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Halozyme Therapeutics 5-Year Yield-on-Cost %?

Halozyme Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Halozyme Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



LTS:0J2O's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.82
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Halozyme Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Halozyme Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's 5-Year Yield-on-Cost % falls into.



Halozyme Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Halozyme Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Halozyme Therapeutics  (LTS:0J2O) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Halozyme Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics (LTS:0J2O) Business Description

Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics (LTS:0J2O) Headlines

No Headlines